初治、体能状态差的非小细胞肺癌和表皮生长因子受体突变患者中的“拉撒路反应” - Suppr

Suppr

超能文献

The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation.

作者信息

Langer Corey J

出版信息

J Clin Oncol. 2009 Mar 20;27(9):1350-4. doi: 10.1200/JCO.2008.20.4859. Epub 2009 Feb 17.

DOI:10.1200/JCO.2008.20.4859

PMID:19224840

Abstract

摘要

相似文献

The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation.初治、体能状态差的非小细胞肺癌和表皮生长因子受体突变患者中的“拉撒路反应”

J Clin Oncol. 2009 Mar 20;27(9):1350-4. doi: 10.1200/JCO.2008.20.4859. Epub 2009 Feb 17.

Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.利用表皮生长因子受体（EGFR）状态实现个性化治疗：肺癌研究人员取得了一项里程碑式成果。

J Natl Cancer Inst. 2009 Aug 5;101(15):1039-41. doi: 10.1093/jnci/djp243. Epub 2009 Jul 28.

Targeting EGFR in non-small-cell lung cancer.非小细胞肺癌中表皮生长因子受体的靶向治疗

N Engl J Med. 2005 Jul 14;353(2):200-2. doi: 10.1056/NEJMe058113.

Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.靶向治疗时代的营养状况：营养不良是表皮生长因子受体激活突变的非小细胞肺癌的一个预后因素。

Korean J Intern Med. 2016 Nov;31(6):1140-1149. doi: 10.3904/kjim.2015.062. Epub 2016 Mar 28.

EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer.日本肺癌患者中表皮生长因子受体（EGFR）突变状态及吉非替尼治疗的预后

Lung Cancer. 2006 Jan;51(1):135-6. doi: 10.1016/j.lungcan.2005.09.004. Epub 2005 Nov 28.

Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.晚期非小细胞肺癌中的表皮生长因子受体突变与酪氨酸激酶抑制剂治疗

Technol Eval Cent Assess Program Exec Summ. 2011 Mar;25(6):1-5.

First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?携带激活型表皮生长因子受体突变的晚期非小细胞肺癌的一线治疗：表皮生长因子受体酪氨酸激酶抑制剂还是化疗？

Curr Opin Oncol. 2011 Mar;23(2):131-2. doi: 10.1097/CCO.0b013e328341ee26.

Optimising therapy for EGFR-addicted NSCLC: just the start.优化针对EGFR依赖型非小细胞肺癌的治疗：这只是开始。

Lancet Oncol. 2012 Mar;13(3):216-7. doi: 10.1016/S1470-2045(12)70037-2. Epub 2012 Jan 26.

Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.预测接受表皮生长因子酪氨酸激酶抑制剂治疗的非小细胞肺癌患者的临床获益情况。

Cold Spring Harb Symp Quant Biol. 2005;70:483-8. doi: 10.1101/sqb.2005.70.048.

Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer?吉非替尼一线治疗还是二线治疗：在表皮生长因子受体（EGFR）突变的非小细胞肺癌治疗中，治疗时机决定一切吗？

Am J Respir Crit Care Med. 2008 Oct 15;178(8):783-5. doi: 10.1164/rccm.200806-910ED.

引用本文的文献

Unexpected "Lazarus response" to single-agent bevacizumab in heavily pretreated patients with HER2-positive breast cancer.在接受过大量治疗的HER2阳性乳腺癌患者中，对单药贝伐单抗出现意外的“拉撒路效应”。

Explor Target Antitumor Ther. 2023;4(6):1157-1164. doi: 10.37349/etat.2023.00189. Epub 2023 Dec 6.

The Revolution of Immunotherapy in Gynecological Cancers: The Lazarus Effect in Endometrial Cancer.妇科癌症免疫治疗的革命：子宫内膜癌中的拉撒路效应

J Clin Med. 2023 Aug 25;12(17):5540. doi: 10.3390/jcm12175540.

Changes in the concentration of EGFR-mutated plasma DNA in the first hours of targeted therapy allow the prediction of tumor response in patients with EGFR-driven lung cancer.在靶向治疗的最初几个小时内，表皮生长因子受体（EGFR）突变的血浆DNA浓度变化能够预测EGFR驱动的肺癌患者的肿瘤反应。

Int J Clin Oncol. 2022 May;27(5):850-862. doi: 10.1007/s10147-022-02128-6. Epub 2022 Feb 16.

Lazarus Response to Tepotinib for Leptomeningeal Metastases in a Patient With Exon 14 Skipping Mutation-Positive Lung Adenocarcinoma: Case Report.拉扎勒斯反应：特泊替尼治疗14号外显子跳跃突变阳性肺腺癌患者软脑膜转移的病例报告

JTO Clin Res Rep. 2021 Jan 19;2(3):100145. doi: 10.1016/j.jtocrr.2021.100145. eCollection 2021 Mar.

Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.舒尼替尼治疗伴有 FLT3 扩增的转移性结直肠癌（mCRC）患者：靶向药物和分析利用注册研究（TAPUR）的结果。

Target Oncol. 2020 Dec;15(6):743-750. doi: 10.1007/s11523-020-00752-8.

Progress in individualized treatment for EGFR-mutated advanced non-small cell lung cancer.EGFR 突变型晚期非小细胞肺癌个体化治疗进展。

Proc Jpn Acad Ser B Phys Biol Sci. 2020;96(7):266-272. doi: 10.2183/pjab.96.020.

Etiologies of delayed diagnosis and six-month outcome of patients with newly diagnosed advanced lung cancer with respiratory failure at initial presentation.新发呼吸衰竭的晚期肺癌患者延迟诊断的病因和六个月的预后。

Thorac Cancer. 2020 Sep;11(9):2672-2680. doi: 10.1111/1759-7714.13604. Epub 2020 Aug 6.

Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden.免疫检查点抑制剂在微卫星不稳定高、疾病负担重且与高疾病负担相关的终末期癌症和较差表现状态患者中的疗效和安全性。

Oncologist. 2020 Sep;25(9):803-809. doi: 10.1634/theoncologist.2020-0014. Epub 2020 May 20.

Cerebral Thromboembolism after Lobectomy for Lung Cancer: Pathological Diagnosis and Mechanism of Thrombus Formation.肺癌肺叶切除术后的脑血栓栓塞：血栓形成的病理诊断及机制

Cancers (Basel). 2019 Apr 5;11(4):488. doi: 10.3390/cancers11040488.

Ceritinib for an anaplastic lymphoma kinase rearrangement-positive patient previously treated with alectinib with poor performance status.色瑞替尼用于一名既往接受阿来替尼治疗且体能状态较差的间变性淋巴瘤激酶重排阳性患者。

Onco Targets Ther. 2018 Dec 17;12:15-19. doi: 10.2147/OTT.S186213. eCollection 2019.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验